Cellular distribution by 2-photon fluorescence of complexes of metallic radioisotopes for imaging and therapy

用于成像和治疗的金属放射性同位素复合物的 2 光子荧光细胞分布

• 批准号: G0901654/1
• 负责人: Stephen Faulkner
• 金额: $ 17.83万
• 依托单位: University of Oxford
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2010
• 资助国家: 英国
• 起止时间: 2010 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0901654%2F1
• 关键词: Cellular; distribution; photon; fluorescence; complexes

Diagnostic medical imaging using radioactive isotopes (PET or SPECT imaging) is an important tool for clinicians to be able to assess patients both before and after treatment and thence to monitor progress. Many of the compounds used contain radioactive metals such as technetium, copper and indium. Detection of the radiation emitted from a patient following injection of the radioactive compound gives images with a resolution of 1-2mm which show for instance the location of a tumour. However once inside the body the radioactive compounds are taken up in cells and this can determine how effectively an imaging agent targets a disease site. PET and SPECT imaging cannot be used to uncover what happens within cells as these are much smaller than the resolution limit of 1-2mm. Some compounds will emit ultraviolet or visible radiation following excitation with radiation at a different wavelength; a phenomenon known as fluorescence. This has much higher resolution than PET or SPECT and we propose to use this technique to reveal how potential metal based PET and SPECT imaging agents are behaving within living cells. This requires the design of compounds that not only target specific disease sites but are also fluorescent. The information from fluorescence will give invaluable information about the mechanisms by which the compounds are trapped at the target disease sites and this can be then be used to redesign the compound to improve its imaging performance. Diagnostic imaging is now a key part of modern medicine and improved PET and SPECT agents would make a significant contribution to obtaining more accurate diagnosis for patients and enabling the treatment to be tailored to an individual patients needs. This concept of personalised medicine is seen worldwide as a major goal for the future.

使用放射性同位素的诊断医学成像（PET或SPECT成像）是临床医生能够在治疗前后评估患者并由此监测进展的重要工具。许多使用的化合物含有放射性金属，如锝，铜和铟。在注射放射性化合物之后检测从患者发射的辐射给出分辨率为1- 2 mm的图像，其显示例如肿瘤的位置。然而，一旦进入体内，放射性化合物就会被细胞吸收，这可以决定成像剂靶向疾病部位的有效性。PET和SPECT成像不能用于揭示细胞内发生的情况，因为它们远小于1- 2 mm的分辨率极限。一些化合物在不同波长的辐射激发后会发出紫外线或可见光辐射;这种现象称为荧光。这具有比PET或SPECT高得多的分辨率，我们建议使用这种技术来揭示潜在的基于金属的PET和SPECT成像剂在活细胞内的行为。这就需要设计出不仅能靶向特定疾病部位，而且能发出荧光的化合物。来自荧光的信息将提供有关化合物被捕获在目标疾病部位的机制的宝贵信息，然后可以用于重新设计化合物以改善其成像性能。诊断成像现在是现代医学的关键部分，并且改进的PET和SPECT试剂将为获得对患者的更准确的诊断以及使治疗能够针对个体患者的需求做出重大贡献。这种个性化医疗的概念在世界范围内被视为未来的主要目标。